A5086533366- Adrenal and Paraganglionic Tumors
- Pituitary Gland Disorders and Treatments
- Cancer, Hypoxia, and Metabolism
- Hormonal Regulation and Hypertension
- Glioma Diagnosis and Treatment
- German Literature and Culture Studies
- Neuroendocrine regulation and behavior
- Public Administration and Political Analysis
- Ovarian cancer diagnosis and treatment
- Stress Responses and Cortisol
- Hepatocellular Carcinoma Treatment and Prognosis
- Growth Hormone and Insulin-like Growth Factors
- Nigella sativa pharmacological applications
- Menstrual Health and Disorders
- Cancer, Lipids, and Metabolism
- Respiratory Support and Mechanisms
- Sperm and Testicular Function
- Childhood Cancer Survivors' Quality of Life
- Liver Disease Diagnosis and Treatment
- Reproductive Biology and Fertility
- Cardiac Arrest and Resuscitation
- Vestibular and auditory disorders
- Toxin Mechanisms and Immunotoxins
- Emergency and Acute Care Studies
- Maternal Mental Health During Pregnancy and Postpartum
University of Turin
2019-2025
Ospedale San Luigi Gonzaga
2019-2024
Hôpital des Enfants
2017
Clinical Hospital No. 8
1991
Adrenocortical carcinoma (ACC) has an aggressive but variable clinical course. Prognostic stratification based on the European Network for Study of Adrenal Tumours stage and Ki67 index is limited. We aimed to demonstrate prognostic role a points-based score (S-GRAS) in large cohort patients with ACC.This multicentre, retrospective study ACC who underwent adrenalectomy.The S-GRAS was calculated as sum following points: tumour (1-2 = 0; 3 1; 4 2), grade (Ki67 0-9% 10-19% ≥20% 2 points),...
Few data exist about the clinical course of acromegaly, surgical and medical outcomes in patients with GH- prolactin cosecreting pituitary adenomas (GH&PRL-PAs). Nevertheless, some series described a more aggressive clinic-radiological behavior than growth hormone-secreting (GH-PAs).
Abstract Context Because of the rarity adrenocortical cancer (ACC), only a few population-based studies are available, and they reported limited details in characterization patients their treatment. Objective To describe nationwide cohort presentation with ACC, treatment strategies, potential prognostic factors. Methods Retrospective analysis 512 diagnosed 12 referral centers Italy from January 1990 to June 2018. Results ACC as incidentalomas accounted for overall 38.1% cases, frequency that...
Objective Many patients with adrenocortical carcinoma (ACC) suffer from tumor recurrence despite radical surgery. Evidence on the post-operative use of mitotane is controversial and no predictors response are available. We aimed to assess whether adjuvant treatment may prolong survival in non-metastatic ACC following complete resection at high risk benefit treatment. Design methods retrospectively reviewed data 152 followed San Luigi Gonzaga Hospital: 100 were treated 52 left untreated...
Mitotane is used as a post-operative adjuvant treatment for patients with adrenocortical carcinoma. Monitoring of plasma mitotane concentrations recommended, but we do not know what impact target have on patient outcome. To answer this question, retrospectively analyzed records in the Lysosafe Online® database (HRA Pharma, France) who were treated ≥6 months and had ≥3 measurements levels during follow-ups at 11 tertiary centers Italy from 2005 to 2017. We identified 110 median 46 (IQR,...
Mitotane is widely used for the treatment of adrenocortical cancer (ACC), although drug-related toxicity complicates its use. The aim this study to assess comprehensively different endocrine and metabolic unwanted effects drug, provide data on supportive therapies. We retrospectively analyzed 74 ACC patients adjuvantly treated with mitotane ≥12 months. During period (40 months, 12–195), 32.4% needed replacement therapy mineralocorticoid deficit, 36.2% hypothyroidism 34.3% male hypogonadism....
Increasing evidence supports the presence of oxytocin deficiency (OXT-D) in patients with hypopituitarism and hypothalamic damage (HHD), that might be associated neuropsychological deficits sexual dysfunction, leading to worse quality life (QoL). Therefore, identifying a provocative test diagnose an OXT-D will important. Corticotropin-releasing hormone (CRH) is candidate for such as it increases secretion animal models. This study aimed examine effects CRH on release HHD compared healthy...
Mitotane is the only approved drug for advanced adrenocortical carcinoma (ACC) and no biomarkers are available to predict attainment of therapeutic plasma concentrations clinical response. Aim study was evaluate suitability cytochrome P450(CYP)2W1 CYP2B6 single nucleotide polymorphisms (SNPs) as biomarkers. A multicenter cohort including 182 ACC patients (F/M = 121/61) treated with mitotane monotherapy after radical resection (group A, n 103) or in not completely resectable, recurrent...
Mitotane is the main option of treatment for advanced adrenocortical carcinoma (ACC). However, limited evidence available regarding impact plasma mitotane levels on patient outcome. To address this question, we retrospectively analyzed patients with ACC treated ≥3 months, measurements reported in Lysosafe Online® database (HRA Pharma, France), followed at 12 tertiary centers Italy from 2005 to 2017. We identified 80 patients, initially alone (56.2%) or plus chemotherapy (43.8%). The...
A relevant issue on the treatment of adrenocortical carcinoma (ACC) concerns optimal duration adjuvant mitotane treatment. We tried to address this question, assessing whether a correlation exists between and recurrence-free survival (RFS) patients with ACC. conducted multicenter retrospective analysis 154 ACC treated for ≥12 months after radical surgery who were free disease at stop. During median follow-up 38 months, 19 (12.3%) experienced recurrence. calculated RFS (RFSAM), from landmark...
The management of adrenocortical carcinoma (ACC) recurrences remains controversial, and we present herein our experience with postoperative ACC recurrences.Retrospective analysis in a single reference center 106 patients recurrence.The median follow-up was 45 months, the recurrence-free survival (RFS) 12 months (IQR 6-23), overall (OS) 29-75). occurred as unique lesion (group A) 35.8%, multiple lesions organ B) 20.8%, affecting organs C) 43.4% patients. Baseline characteristics stratified by...
Mitotane is a steroidogenesis inhibitor and adrenolytic drug used for treatment of adrenocortical cancer (ACC). therapy causes adrenal insufficiency requiring glucocorticoid replacement in all patients. However, it unclear whether chronic with mitotane induces complete destruction zona fasciculata hypothalamic-pituitary-adrenal (HPA) axis can recover after cessation. Our objective was to assess the HPA recovery cohort patients cessation adjuvant ACC. We retrospectively reviewed patient files...
(1) Background: In clinical settings, data regarding sex are rarely investigated. women, factors such as body size and composition, hormonal variations, metabolism, access to care systems therapy could strongly influence the pharmacological management outcome of therapy. To underline this sex-related difference, we retrospectively collected from adrenocortical carcinoma patients treated with mitotane, then evaluated pharmacokinetics parameters. (2) Methods: A fully validated chromatographic...
Whether environmental pollution may influence adrenocortical carcinoma (ACC) development remains largely unknown. The aim of this study was to evaluate the impact exposition pollutants on ACC presentation and prognosis in Italy. A retrospective analysis done 500 patients affected by ACC, who were diagnosed 12 reference centers Italy from 1990 2018 followed-up for a median 37.5 months (interquartile range, IQR, 11-83). Patients stratified according to: i) residence Sites National Interest...
Adrenocortical carcinomas (ACC) are often associated with cortisol and/or androgen hypersecretion. Metirapone and osilodrostat used for syndrome control despite they induce levels increase. Abiraterone acetate (AA) is an irreversible inhibitor of 17α-hydroxylase/C17, 20-lyase (CYP17) that blocks the adrenal synthesis androgens. The aim this study was to assess efficacy AA in ACC patients Cushing's syndrome. ABACUS (NCT 03145285) a phase II trial aiming activity normalizing 24-h urinary free...
Abstract Disclosure: S. Puglisi: None. A. Calabrese: F. Ferraù: Y. Alessi: M. Laganà: Grisanti: Ceccato: C. Scaroni: G. Di Dalmazi: Stigliano: B. Altieri: L. Canu: Luconi: P. Loli: De Martino: E. Arvat: Palmieri: Perotti: V. Basile: Berchialla: Urru: Berruti: Pia: Reimondo: Cannavò: Terzolo: Background: Whether environmental pollution may influence adrenocortical carcinoma (ACC) development remains largely unknown. The aim of this study was to evaluate the impact exposition pollutants on ACC...
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)
Abstract Background: Adrenocortical carcinoma (ACC) has an aggressive but heterogeneous behaviour. ENSAT stage and Ki67 proliferation index are used to predict clinical outcome limited in distinguishing patients with different risk of disease progress. We aimed validate the prognostic role a previously proposed points-based score (mGRAS) large ACC cohort. Methods: included who underwent adrenalectomy between 2010 2019, had complete histopathological data, did not participate our previous...
The behavior of tumor-associated trypsin inhibitor (TATI) as a marker for gynecological cancer was studied in control population and patients with different benign malignant diseases. When cut-off level 21.4 micrograms/l used the specificity 100% sensitivity tumors low cervical corpus cancer, 13% 14%, respectively, whereas it 33% all ovarian tumors, reaching 60% mucinous type. There clear correlation between TATI stage.
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)